# Leucine-Responsive Regulatory Protein-Mediated Repression of *clp* (Encoding CS31A) Expression by L-Leucine and L-Alanine in *Escherichia coli*

Cécile Crost,<sup>1,2</sup> Annie Garrivier,<sup>1</sup> Josée Harel,<sup>2</sup> and Christine Martin<sup>1</sup>\*

*Laboratoire de Microbiologie, Institut National de la Recherche Agronomique, 63122 St-Gene`s-Champanelle, France,*<sup>1</sup> and Département de Pathologie et Microbiologie, Université de Montréal, St-Hyacinthe QC J2S 7C6, Canada<sup>2</sup>

Received 16 July 2002/Accepted 16 December 2002

**CS31A produced by septicemic and diarrheic** *Escherichia coli* **belongs to the Pap-regulatory family of adhesive factors, which are under methylation-dependent transcriptional regulation. Common features of operons encoding members of this family include two conserved GATC sites in the upstream regulatory region, and transcriptional regulators homologue to the PapB and PapI proteins. Methylation protection of GATC sites was previously shown to be dependent on the leucine-responsive regulatory protein (Lrp). Lrp and ClpB, the PapB equivalent, repressed** *clp* **basal transcription. A PapI homologue (AfaF) was required together with Lrp to establish the phase variation control, which gave rise to phase-ON cells that expressed CS31A and** phase-OFF cells that did not express CS31A. In phase-OFF cells, the GATC<sub>dist</sub> site was methylated and the GATC<sub>prox</sub> site was protected from methylation, whereas in phase-ON cells, the inverse situation was found. **Unlike Pap fimbriae, CS31A synthesis was dramatically reduced in media containing L-alanine or L-leucine. L-Alanine prevented the OFF-to-ON switch, locking** *clp* **expression in the OFF phase, whereas L-leucine repressed transcription without obvious effect on the switch frequency of phase variation. In phase-variable** cells, leucine and alanine promoted methylation of GATC<sub>dist</sub> and methylation protection of GATC<sub>prox</sub>, increas**ing the methylation pattern characteristic of repressed cells. Furthermore, alanine prevented the AfaF**dependent methylation protection of GATC<sub>dist</sub> and thus the appearance of phase-ON cells. In addition, **analysis of** *clp* **expression in a Lrp-negative background indicated that alanine and leucine also repressed** *clp* **transcription by a methylation-independent mechanism.**

Lrp (leucine-responsive regulatory protein) is a global transcriptional regulator of metabolism in *Escherichia coli*. It affects the expression of a number of operons involved in amino acid biosynthesis and degradation, nutrient transport, and formation of fimbriae. Many of these operons are also subject to control by leucine and alanine. All the possible regulatory patterns in response to Lrp and leucine have been demonstrated. Lrp positively regulates some operons and negatively regulates others. In each category, leucine antagonizes the action of Lrp on certain operons and potentiates it on other operons. Some other positively or negatively regulated operons are insensitive to leucine. In a number of cases, alanine has been shown to have a similar effect to leucine (for reviews, see references 7 and 31). It has been shown that leucine antagonizes the activating action of Lrp on *ilvIH* and *gltBDF* promoters and the repressive action of Lrp on the *lysU* promoter by reducing the affinity of Lrp for its binding sites (13, 25, 37). To explain why some operons are insensitive to leucine even when the cell contains enough leucine to bind to Lrp, Ernsting et al. suggested that the effect of leucine on positively regulated genes depends on the effective in vivo concentration of Lrp (13). At high Lrp concentrations, Lrp binds to the promoters regardless of the presence or absence of leucine, whereas at low Lrp concentrations, the activities of these promoters is

\* Corresponding author. Mailing address: Laboratoire de Microbiologie, Institut National de la Recherche Agronomique, 63122 St-Genès-Champanelle, France. Phone: (33) 4 73 62 42 47. Fax: (33) 4 73 62 45 81. E-mail: cmartin@clermont.inra.fr.

leucine sensitive. If Lrp binds to different promoters with different affinities, the target genes with the lowest affinity for Lrp are the most sensitive to leucine. However, such a model does not explain how leucine can potentiate the action of Lrp.

Regulation of expression of fimbriae belonging to the Pregulatory family involves Lrp, which directly interacts with another regulatory protein encoded by the fimbrial operons, a PapI homologue. Expression of all the operons so far studied belonging to this family is insensitive to leucine, except for the *clp* and *foo* operons encoding CS31A and  $F165<sub>1</sub>$  fimbriae, respectively (19, 28). Fimbrial operons belonging to the P-regulatory family share important regulatory features. They are subject to phase variation control (except *fae*, encoding K88), defined as the ability of cells to switch in a reversible manner between fimbriated, phase-ON cells and afimbriated, phase-OFF cells. Lrp and a PapI homologue are required for the switch to occur (20, 26). The Lrp target regulatory region contains two GATC sites that are spaced 102 or 103 bp apart. The differential methylation status of these sequences determines the binding of Lrp, because Lrp binds only nonmethylated or hemimethylated GATC sites (34). PapI or its homologues have the capacity to displace Lrp from one binding site to another (24, 33). The activity of the promoter depends on the binding of Lrp, since Lrp activates expression when bound to certain sites and represses expression when bound to others (33, 38, 40). All operons also encode a PapB homologue that appears to play a dual role in the control of *pap* expression. Low levels of PapB activate *papI* transcription, whereas high levels suppress *papBA* expression (3, 18, 42). Distinct regula-



FIG. 1. The *clp* regulatory region, sequences surrounding the *clp* operon, and operon fusion constructs. The nucleotide sequence of the *clp* regulatory region is shown at the top, with the GATC sites in bold. The GenBank accession number for this sequence is L48184. The organization of DNA surrounding the *clp* operon is shown below the regulatory region. Boxes with arrowheads indicate the positions of sequences with high homologies to sequences present in data banks as found using the BLASTn program (National Center for Biotechnology Information). The operon fusion constructs are shown in expanded scale at the bottom. The *clpB* gene is truncated in  $\lambda$ 15 (black box) and is entire in  $\lambda$ 6 (hatched box). P indicates the putative *clp* promoter.

tory features can also be observed between members of the P-regulatory family. Null mutations in the *lrp* gene reduce the transcription of some operons, such as *pap*, *pef*, *sfa*, and *daa* (4, 32, 39), and increase the transcription of others, such as *clp* or *fae* (22, 28). PapI homologues activate the transcription of *pap*, *sfa*, *daa*, and *foo* (33, 39) and repress the transcription of *pef*, *fae*, and *clp* (22, 28, 32).

CS31A, encoded by the *clp* operon is produced by septicemic and enterotoxigenic bovine (9, 16) and human (23) *E. coli* strains. In *E. coli* reference strain 31A, CS31A is encoded by a high-molecular-weight plasmid called p31A. CS31A mediates adhesion to Caco-2 and Int-407 cells (12, 23), is required for full bacterial virulence in the rat model, and protects bacteria from phagocytosis by bovine polymorphonuclear neutrophils (J. P. Girardeau, personal communication). In the absence of phase variation, i.e., in the absence of a PapI homologue in the cells, Lrp and the specific regulator ClpB negatively control the basal *clp* expression. Under these conditions, GATC<sub>dist</sub> is methylated whereas GATC<sub>prox</sub> is protected from methylation. Lrp, but not ClpB, is required for methylation protection of  $GATC<sub>prox</sub>$ . Methylation is required for repression (28). Leucine and alanine dramatically reduce CS31A production (16, 29). We have previously shown that alanine represses

basal *clp* transcription twofold in the absence of a PapI homologue and inhibits phase variation in its presence (28).

In this study, CS31A phase variation was examined using AfaF, a PapI equivalent. The influence of AfaF and Lrp on the methylation patterns and their role in phase variation were investigated. The influence of leucine and alanine on *clp* expression and on the methylation pattern was examined. As emphasized by Blomfield, changes in phase variation as opposed to steady-state control could have different outcomes on fimbriae production (1a). Thus, we tried to distinguish the effect of leucine and alanine on each process by studying the steady-state expression (i.e., the basal transcription) and the phase variation in the absence and presence of AfaF.

## **MATERIALS AND METHODS**

Bacterial strains and media. E. coli strains MC4100. $\lambda$ 6, MC4100. $\lambda$ 15, DL844. $\lambda$ 6, and DL844. $\lambda$ 15/1 contain a single chromosomal copy of a *clp-lacZYA* fusion (see Fig. 1). The  $\lambda$ 6 lysogens contain an entire functional *clpB* gene, whereas  $clpB$  is truncated in the  $\lambda$ 15 lysogens (28). DL844. $\lambda$ 15/1 was constructed as previously described to replace DL844. $\lambda$ 15 (28). The PCR assay described by Powell et al. (36) was used to verify that the four strains contained single lysogens. By this method, the DL844. $\lambda$ 15 strain used in a previous study (28) was shown to harbor more than one copy of the prophage, which was not detected by the  $\lambda$  terminase test (2) that was used previously. DL844 is an Lrp-negative

isogenic MC4100 strain (5). ptrf1 and pCLB99 are multicopy recombinant plasmids derived from ptrc99A (Pharmacia Biotech) and express *afaF* and *clpB*, respectively, under the control of the *trc* promoter (28). Luria-Bertani broth, Luria-Bertani agar, M9 minimal broth, and M9 minimal agar were prepared by the method of Miller (30). Glycerol as carbon source was added at 0.2% (wt/vol). Supplements, when appropriate, were used at the following concentrations: 5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside (X-Gal), 40  $\mu$ g ml<sup>-1</sup>; isopropyl-ß-D-thiogalactopyranoside (IPTG), 1 mM; L-leucine or L-alanine, 5 mM; ampicillin, 50  $\mu$ g ml<sup>-1</sup>; and kanamycin, 50  $\mu$ g ml<sup>-1</sup>. Isoleucine (0.4 mM) and valine (0.6 mM) were added to media containing 5 mM leucine. Cultures of strains harboring ptrf1 were done without IPTG to avoid too high an expression of *afaF.*

Assay of  $\beta$ -galactosidase activity. A single bacterial colony picked on M9glycerol agar plates containing X-Gal was used to inoculate an overnight culture in M9-glycerol medium. This culture was diluted 50-fold, grown to logarithmic phase (optical density at 600 nm, 0.5 to 0.8) in M9-glycerol medium supplemented with amino acids as indicated. Cultures were assayed for  $\beta$ -galactosidase activity as described previously (30). For strains showing phase variation, ON (blue) or OFF (white) colonies were picked from M9-glycerol–X-Gal plates as starting material for assays of activity of ON and OFF cultures, respectively. Each experiment was done in duplicate at least five times.

**Calculation of the switch frequency.** Lysogen strains were inoculated onto M9 glycerol–X-Gal plates supplemented with L-leucine or L-alanine or left unsupplemented. Colonies showing a uniform phenotype were resuspended in M9 salts. Appropriate dilutions were spread onto the same medium as the parent colony. After growth, the colonies were scored for a light blue or dark blue phenotype. The switch frequencies were calculated using the formula (*M*/*N*)/*g*, where *M* is the number of cells that underwent phase transition, *N* is the total number of cells evaluated, and *g* is the total number of generations, estimated to be 25, that gave rise to the colony.

**DNA sequencing.** For sequencing of DNA regions adjacent to the *clp* operon, the genome walker kit from Clontech Laboratories was used. p31A DNA was digested by restriction endonucleases that generate blunt ends and ligated to the adaptors provided in the kit as specified by the manufacturer. PCR amplification using the adaptor primer and a *clp*-specific primer allowed sequencing of unknown DNA fragments adjacent to *clp* without previous cloning. Templates for DNA sequencing were prepared using a PE Applied Biosystem dye terminator cycle-sequencing kit. Products were analyzed on an ABI Prism 310 DNA sequencer. Oligonucleotides were from Eurogentec or MWG Biotech.

**DNA hybridizations.** For chromosomal MC4100. $\lambda$ 6 DNA purification, a single blue or a single white colony was picked from M9-glycerol–X-Gal agar, resuspended in M9 salts, and used to inoculate three flasks containing the appropriate medium. Isoleucine (0.4 mM) and valine (0.6 mM) were added to the medium containing 5 mM leucine. Chromosomal DNA was isolated from overnight cultures using the DNeasy tissue kit (Qiagen). Aliquots of the cultures used for DNA purification were plated on the corresponding medium to calculate the percentage of ON cells. Digestions with restriction endonucleases *Mbo*I and *Dpn*I were performed as specified by the manufacturer. DNA restriction fragments were separated by electrophoresis on 1.5% agarose in TBE buffer and transferred to a nylon membrane (Hybond N+; Amersham Biotech) in  $20\times$  SSC (0.3 M sodium citrate, 0.33 M NaCl [pH 7.0]) using a vacuum blotter (Appligene). Transfer was carried out at 4.5 kPa for 60 min. DNA fragments were cross-linked to the filter with UV light by using a Spectrolinker (Spectronics Corp.). The filter was probed with digoxigenin-labeled DNA (240 bp) generated by PCR using the PCR DIG probe synthesis kit (Roche) and primers RU (5-CCTGTTTGATTTCGTGC-3) and RD (5-CTGCAGCGAAGATTATC-3). Hybridization was detected by chemiluminescence using CDP-Star (NEN) as a substrate for alkaline phosphatase. Quantification was performed by densitometry analysis using the Diversity DataBase software from Bio-Rad.

# **RESULTS**

**CS31A phase variation.** To analyze CS31A phase variation, we attempted to clone the *clp papI* homologue. By analogy to other fimbrial operons belonging to the P regulatory family, we supposed that the *papI* homologue would be present upstream or downstream next to the *clp* operon. However, nucleotide sequencing revealed that diverse insertion sequences and transposons flank the *clp* operon up to 7.8 kb upstream and 4.6 kb downstream. An open reading frame presenting 44% identity to the functional *clpB* gene is present 3 kb downstream of the *clp* operon but is isolated and also flanked by insertion sequences or unknown sequences (Fig. 1). Furthermore, our numerous efforts to clone the *papI* homologue from plasmid p31A were unsuccessful. PCR assays using *afaF*- or *papI*-derived primers failed to amplify a DNA fragment from p31A. A p31A DNA library was constructed and hybridized at high stringency with a 400-bp *afaF* probe (28). Hybridization was found only with a 65-bp sequence derived from an insertion sequence. No more hybridization was found after deletion of this sequence in the probe, even at low stringency. Transformation of p31A in MC4100.λ6 or MC4100.λ15 failed to restore phase variation. Either this gene indeed exists on p31A and we were not able to clone it, or CS31A phase variation is controlled by a PapI homologue encoded to a related chromosomally located operon. We therefore decided to analyze CS31A phase variation by using in *trans* AfaF, the PapI homologue belonging to the *afa-3* gene cluster. Afa-3 is a nonfimbrial adhesin (15) with a structural organization more closely related to CS31A than to P-fimbriae. AfaF was chosen because the ClpB and AfaA regulators (PapB homologues) have 60.6% amino acid sequence identity (28). Furthermore, we have shown previously that plasmid ptrf1, harboring *afaF* under the control of the *trc* promoter, promotes phase variation when introduced into *E. coli* strains harboring *clp-lacZYA* transcriptional fusions (28). To study transcriptional *clp* regulation, we used different strains that harbor a single chromosomal *clp*lacZYA transcriptional fusion, with ( $\lambda$ 6 lysogens) or without  $(\lambda 15$  lysogens) an intact *clpB* gene (Fig. 1). The fusions were created either in MC4100 *E. coli* or in DL844 *E. coli* to provide  $Lrp^{+}$  or  $Lrp^{-}$  backgrounds, respectively. As already demonstrated, uniform blue colonies arose by plating  $\lambda$ 6 or $\lambda$ 15 lysogens on M9-glycerol plates containing X-Gal in the absence of AfaF (28). Table 1 shows that ClpB and Lrp regulated the *clp* basal transcription even in the absence of the phase variation control (i.e., in the absence of AfaF): comparison of DL844. $\lambda$ 6  $(493 \text{ MU})$  with MC4100. $\lambda$ 6 (112 Miller units [MU]) showed that Lrp played a repressive role. Similarly, comparison of MC4100.λ15 (775 MU) with MC4100.λ6 (112 MU) showed that ClpB also played a repressive role, which was previously demonstrated in MC4100. $\lambda$ 15 complemented in *trans* by pCLB99, a multicopy plasmid expressing *clpB* under the control of the *trc* promoter (28). It is not clear why the transcription was not totally derepressed in the DL844. $\lambda$ 15/1 strain, which lacks Lrp and ClpB (see Discussion). After the plasmid encoding AfaF was introduced into the strains, phase variation occurred only in the  $Lrp^+$  backgrounds, with emergence of a majority of white colonies among the blue ones, indicating a global repressive effect. Measurements of the  $\beta$ -galactosidase activity of  $Lac^+$  (phase-ON) and  $Lac^-$  (phase-OFF) colonies are reported in Table 1. Transcription was highly repressed in phase-OFF cells (18 and 38 MU in  $ClpB^+$  and  $ClpB^-$  strains, respectively). When AfaF was overexpressed due to the addition of 1 mM IPTG to the growth medium, the colonies presented a uniform Lac<sup>-</sup> phenotype on M9-glycerol-X-Gal agar plates, indicating that transcription of *clp-lacZ* was completely inactive (data not shown). Without Lrp, transcription was locked in the ON phase [DL844.λ6(ptrf1), 338 MU]. Thus, Lrp was required for repression of the promoter and emergence of phase-OFF cells. However, when we took into account the

TABLE 1. Transcription levels of *clp-lacZYA* in different media and different genetic backgrounds

Strain	Genotype	Growth median <sup>a</sup>	<b>Starting</b> colony	Switch frequency		β-Galactosidase	% of phase-
				ON to OFF	OFF to ON	activity $(MU)^c$	ON cells
<b>MC4100.λ6</b>	$clpB^+$ lrp <sup>+</sup> afaF	M <sup>9</sup> M9-alanine M9-leucine	$\mathbf{U}^b$ U U			$112 \pm 9$ $36 \pm 3$ $53 \pm 7$	
$MC4100.\lambda6(\text{ptrf1})$	$clpB^+$ lrp <sup>+</sup> afa $F^+$	M <sup>9</sup> M9-leucine	Phase ON Phase OFF Phase ON Phase OFF	$3.16 \times 10^{-2}$ $3.24 \times 10^{-2}$	$1.47 \times 10^{-3}$ $1.81 \times 10^{-3}$	$87 \pm 21$ $18 \pm 5$ $10 \pm 3$ $8 \pm 3$	21.1 3.68 19.12 4.53
<b>DL844.16</b>	$clpB^+$ lrp afaF	M <sup>9</sup> M9-alanine M9-leucine	U U U			$493 \pm 59$ $197 \pm 39$ $250 \pm 3$	
$DL844.\lambda6(\text{ptrf1})$	$clpB^+$ lrp afa $F^+$	M <sup>9</sup> M9-alanine M9-leucine	U U U			$338 \pm 57$ $163 \pm 33$ $200 \pm 66$	
MC4100.λ15	$clpB$ lrp <sup>+</sup> afaF	M <sup>9</sup> M9-alanine M9-leucine	U U U			$775 \pm 60$ $170 \pm 20$ $238 \pm 71$	
$MC4100.\lambda15(\text{ptrf1})$	$clpB$ lrp <sup>+</sup> afaF <sup>+</sup>	M <sup>9</sup> M9-alanine M9-leucine	Phase ON Phase OFF U Phase ON Phase OFF	$2.37 \times 10^{-2}$ $2.64 \times 10^{-2}$	$1.15 \times 10^{-3}$ $1.16\times10^{-3}$	$336 \pm 144$ $38 \pm 11$ $11 \pm 4$ $152 \pm 30$ $31 \pm 4$	40.35 2.96 33.6 2.91
DL844. $\lambda$ 15/1	$clpB$ lrp afa $F$	M <sup>9</sup> M9-alanine M9-leucine	U U U			$276 \pm 36$ $202 \pm 28$ $295 \pm 47$	
$DL844.\lambda15/1(\text{ptrf1})$	$clpB$ lrp afa $F^+$	M <sup>9</sup> M9-alanine M9-leucine	U U U			$278 \pm 81$ $221 \pm 44$ $290 \pm 26$	

*<sup>a</sup>* Glycerol is the carbon source. Media containing leucine are supplemented with isoleucine (0.4 mM) and valine (0.6 mM).

*<sup>b</sup>* U, uniform phenotype of the colonies.

<sup>*c*</sup> Results are the means  $\pm$  standard deviations of at least five independent experiments made in duplicate.

fraction of phase ON cells in the MC4100. $\lambda$ 6(ptrf1) colonies, it appeared that the transcription level of phase-ON cells was higher than in the absence of AfaF (87 MU for 21% of phase ON-cells versus 112 MU for 100% of phase-ON cells). Since AfaF had no regulatory effect in an  $Lrp^-$  background [Table 1,  $DL844.\lambda15/1$  versus  $DL844.\lambda15/1(\text{ptrf1})$ ], our data suggest that AfaF modulated the regulatory activity of Lrp by increasing its repressive effect in a large fraction of cells (phase OFF) and by conferring to it an activating activity in the remaining fraction (phase ON). In contrast, ClpB was not required for the phase variation to occur. The ClpB-dependent repression was still effective in phase-ON cells [compare MC4100λ6(ptrf1) to MC4100.λ15(ptrf1)]. However, results obtained with  $MC4100.\lambda15$ (ptrf1) were difficult to analyze: while  $Lac^-$  colonies were really white,  $Lac^+$  colonies presented all the gradations of blue, leading to a fraction of phase-ON cells in a  $Lac<sup>+</sup>$  colony that varied greatly from one experiment to another [which was not the case for MC4100. $\lambda$ 6(ptrf1)], ranging from 6 to 78%. Such a variability has already been observed in *Salmonella enterica* serovar Typhimurium populations expressing Pef fimbriae (32), but it remains unexplained.

**Influence of leucine and alanine on** *clp* **expression.** Because CS31A is one of the only two known P-related fimbriae sensitive to leucine and alanine, we analyzed in further detail the effect of these amino acids on *clp* transcription. Alanine abolished *clp* transcription, locking cells in phase OFF (Table 1). In contrast, leucine did not dramatically alter the switch frequency of phase variation. We measured the  $\beta$ -galactosidase activity in different strain backgrounds starting either from a Lac<sup>+</sup> or from a Lac<sup>-</sup> colony grown on M9-glycerol–X-Gal with L-alanine or L-leucine (Table 1). Alanine and, to a lesser extent, leucine dramatically decreased *clp* transcription in MC4100. $\lambda$ 6 and MC4100. $\lambda$ 15 strains in the presence and absence of AfaF. Repression was also observed in the Lrp  $ClpB<sup>+</sup>$  (DL844. $\lambda$ 6) backgrounds with and without AfaF. However, in the simultaneous absence of ClpB and Lrp [DL844. $\lambda$ 15 (ptrf1) and DL844. $\lambda$ 15], neither leucine nor alanine repressed *clp* transcription.

**DNA methylation pattern analysis.** In the absence of AfaF (i.e., in the absence of phase variation), the  $GATC_{dist}$  site was methylated and the GATC<sub>prox</sub> site was protected from methylation in about 50% of the DNA molecules whereas both  $GATC<sub>dist</sub>$  and  $GATC<sub>prox</sub>$  sites were methylated in the remaining 50% of DNA molecules. This methylation pattern was similar in  $C1pB<sup>+</sup>$  and  $C1pB<sup>-</sup>$  strains. In an  $Lrp<sup>-</sup>$  background, both GATC sites were methylated in 100% of the molecules (28). By analogy



FIG. 2. Analysis of the in vivo GATC methylation states of the *clp* regulatory region. A Southern blot of chromosomal DNA obtained from MC4100. $\lambda$ 6 (A) and MC4100. $\lambda$ 6(ptrf1) (B) grown in M9-glycerol (lanes 2, 3, and 17 to 20), in M9-glycerol plus alanine (lanes 4, 5, and 13 to 16), or in M9-glycerol plus leucine, isoleucine, valine (lanes 6, 7, and 9 to 12) is shown. For MC4100.A6, a colony grown on M9-glycerol was chosen at random among uniform colonies as the starting material. For MC4100.A6(ptrf1), a Lac<sup>+</sup> and a Lac<sup>-</sup> colony were used as the starting material. The DNA was digested with *Bam*HI plus *Eco*RI and either *Dpn*I (D) or *Mbo*I (M). DNA hybridization was carried out with the digoxigenin-labeled probe indicated in panel C by a horizontal dotted line. The digoxigenin-labeled DNA molecular weight marker VI (Roche) was loaded in lanes 1 and 8. Its fragment sizes are indicated on the left. Size of DNA fragments that hybridized with the probe are shown on the right. (C) Schematic representation of DNA fragments that may hybridize with the probe.

to *pap*, it was concluded that Lrp was bound to the  $GATC<sub>prox</sub>$  site in 50% of the molecules and that the affinity of  $Lrp$  for  $GATC<sub>prox</sub>$ is stronger than for GATC<sub>dist</sub>. To determine whether AfaF, leucine, or alanine modifies the methylation pattern, we performed Southern analyses on MC4100.λ6 and MC4100λ6(ptrf1) DNA. Single colonies cultured on M9-glycerol–X-Gal were used to inoculate M9-glycerol supplemented with the amino acids or left unsupplemented. For MC4100λ6(ptrf1), inoculation was done with either a Lac<sup>+</sup> or a Lac<sup>-</sup> colony. The corresponding percentage of phase-ON cells was calculated. MC4100. $\lambda$ 6 cells presented a uniform phenotype; therefore, a single colony was picked at random. DNA was digested with *Dpn*I, which cuts only methylated GATC sites, or *Mbo*I, which cuts only nonmethylated GATC sites, and hybridized with a digoxigenin DNA probe that encompasses the two GATC sites (Fig. 2). The results obtained (Fig. 2) are schematically represented in Table 2.

In the absence of AfaF and the presence of alanine, fewer than 40% of the DNA molecules presented methylation protection of  $GATC<sub>prox</sub>$  (Fig. 2; Table 2), suggesting that alanine slightly lowered the affinity of Lrp for its target  $GATC<sub>prox</sub>$  site. Leucine altered the methylation pattern in the same way, but its effect was more drastic since only 25% of the DNA molecules were protected from methylation on GATC<sub>prox</sub>.

In the presence of AfaF, the DNA molecules from a Lac colony cultured in M9-glycerol–X-Gal showed methylated  $GATC_{dist}$  sites whereas  $GATC_{prox}$  sites were protected from methylation. Since  $94\%$  of the colonies presented a Lac<sup>-</sup> phenotype, we can assume that this methylation pattern is characteristic of phase-OFF cells and that the method was not sensitive enough to detect molecules corresponding to fewer than 6% of the cells. DNA molecules from a  $Lac<sup>+</sup>$  colony presented two methylation

Starting colony and growth medium <sup>a</sup>	Methylation pattern <sup>b</sup>	$%$ of DNA molecules	$\%$ of Lac $^+$ cells	$%$ of Lac <sup>-</sup> cells
	众 GATC <sub>prox</sub> <b>GATC</b> <sub>dist</sub>	48.5	$\mathrm{NA}^c$	$\rm NA$
Afa $F^-$ , M9	≭ ≭ GATC <sub>dist</sub> GATC <sub>prox</sub>	51.5		
AfaF <sup>-</sup> , M9-alanine	☆ $GATC_{dist}$ GATC <sub>prox</sub>	36.5	$\rm NA$	$\rm NA$
	产 $GATC_{dist}$ GATC <sub>prox</sub>	63.5		
AfaF <sup>-</sup> , M9-leucine	☆ $GATC_{dist}$ GATC <sub>prox</sub>	24.5	$\rm NA$	$\rm NA$
	☆ 产 $GATC_{dist}$ GATC <sub>prox</sub>	75.5		
AfaF <sup>+</sup> Lac <sup>-</sup> , M9	☆ $GATC_{dist}$ GATC <sub>prox</sub>	100	6	94
AfaF <sup>+</sup> Lac <sup>+</sup> , M9	☆ GATC <sub>prox</sub> GATC <sub>dist</sub>	62	44	56
	☆ $GATC_{dist}$ GATC <sub>prox</sub>	37		
	∗ $GATC_{dist}$ GATC <sub>prox</sub>	95		100
AfaF <sup>+</sup> Lac <sup>-</sup> or AfaF <sup>+</sup> Lac <sup>+</sup> M9-alanine	☆ 屳 $GATC_{dist}$ GATC <sub>prox</sub>	5		
	☆ GATC <sub>prox</sub> $GATC_{dist}$	89	5	95
AfaF <sup>+</sup> Lac <sup>-</sup> , M9-leucine	ρ⋩ p٢ GATC <sub>dist</sub> GATC <sub>prox</sub>	$11\,$		
	77 $GATC_{dist}$ GATC <sub>prox</sub>	65		
AfaF <sup>+</sup> Lac <sup>+</sup> , M9-glycerol leucine	☆ ቱ $\overline{\text{GATC}}_{\text{dist}}$ GATC <sub>prox</sub>	$21\,$	12	$88\,$
	☆ $GATC_{dist}$ GATC <sub>prox</sub>	13		

TABLE 2. Methylation patterns of the *clp* regulatory region

*a* The strain used is MC4100. $\lambda$ 6 (ClpB<sup>+</sup> Lrp<sup>+</sup>) harboring or not harboring ptrf1 (AfaF<sup>+</sup> and AfaF<sup>-</sup>, respectively). The carbon source is glycerol. Media containing leucine are supplemented with 0.4 mM isoleucine and 0.6 mM valine. *<sup>b</sup>* Stars indicate methylation of GATC.

*<sup>c</sup>* NA, not applicable (cells present a uniform phenotype).

patterns: 62% of the molecules showed the methylation pattern characteristic of phase-OFF cells, and 37% of the molecules showed the opposite pattern, with GATC<sub>dist</sub> protected from methylation and with methylated  $GATC<sub>prox</sub>$  sites. These patterns correlated well with the 56% Lac<sup>-</sup> colonies and 44% Lac<sup>+</sup> colonies observed in the culture. Thus, we can assume that the characteristic pattern of phase-ON cells is  $GATC<sub>dist</sub>$  protected from methylation and GATC<sub>prox</sub> methylated. Comparison of the methylation patterns of the  $AfaF^-$  and  $AfaF^+$  cells grown in M9-glycerol suggests that AfaF increased the affinity of Lrp for GATC<sub>prox</sub>, producing highly repressed phase-OFF cells, and that in a small proportion of cells, AfaF allowed Lrp binding to GATC<sub>dist</sub>, producing activated phase-ON cells. Together with measurement of  $\beta$ -galactosidase activities, our results indicate that maximal repression requires Lrp binding to

 $GATC<sub>prox</sub>$  and maximal activation Lrp binding to  $GATC<sub>dist</sub>$ . When alanine was added to the growth medium, 100% of the colonies appeared  $Lac^-$ . This phenotype correlated well with 95% of the DNA molecules presenting the methylation pattern characteristic of phase-OFF cells and 5% being fully methylated. Leucine had a less drastic effect on *clp* transcription since phase variation still occurred. The Lac<sup>-</sup> colony presented the same methylation patterns as the colonies cultured in alanine and was composed of  $95\%$  of Lac<sup>-</sup> cells. The Lac<sup>+</sup> colony presented  $12\%$  Lac<sup>+</sup> cells, and  $13\%$  of the DNA molecules showed the methylation pattern characteristic of phase-ON cells in addition to the two methylation patterns observed in the  $Lac$  colony. Comparison of the methylation patterns with and without the amino acids shows that leucine decreased and alanine prevented the AfaF-dependent methylation protection of GATC<sub>dist</sub>. In consequence, alanine prevented the emergence of phase-ON cells. Furthermore, alanine increased the methylation protection of  $GATC<sub>prox</sub>$  since  $95\%$  of the DNA molecules from AfaF<sup>+</sup> cells presented  $GATC<sub>prox</sub>$  protected from methylation in the presence of alanine instead of 62% in its absence.

## **DISCUSSION**

CS31A, encoded by the *clp* operon, belongs to the P-regulatory family of fimbriae. Its expression is subject to a tight control at the transcriptional level, mediated by the global regulator Lrp, as well as by two specific regulators, ClpB and a PapI homologue, and is dramatically repressed by L-leucine and L-alanine. Leucine bound to Lrp modulates the expression of a number of operons by altering the affinity of Lrp for its target sites. In some cases, alanine plays the same role as leucine. The mode of action of leucine on operons subjected to phase variation control, involving an Lrp binding protein of the PapI family, has not been investigated until now. The intensively studied *pap* operon is insensitive to leucine, and CS31A and  $F165<sub>1</sub>$  are the only two fimbriae of the P-regulatory family known to be responsive to leucine and alanine. In this study, we investigated the molecular mechanisms of the phase variation control and the influence of leucine and alanine on *clp* expression by analyzing their effects (i) on the *clp* promoter, which is repressed by Lrp and ClpB independently of phase variation, and (ii) on phase variation, which is mediated by Lrp and the PapI homologue AfaF.

AfaF was used in this study because our numerous efforts to clone the homologous PapI homologue from the p31A virulence plasmid were unsuccessful. These results suggest that p31A does not harbor a *clp* specific homologue to *papI*. The phase variation control observed in wild-type strains could result from a cross talk between *clp* and a chromosomal *pap*-related operon. Recently it has been shown that the reference strain 31A encodes P fimbriae (1). Whether PapI encoded by this *pap* operon indeed crossregulates *clp* transcription has not be yet investigated. Functional complementation with heterologous PapI homologues has already been demonstrated: PefI expressed from a multicopy plasmid activates *papBA* transcription in *E. coli* whereas it represses *pef* transcription in *S. enterica* serovar Typhimurium (32), and PapI, which is a positive regulator of *pap* transcription, represses K88 production, as does the homologous FaeA regulator (22). SfaC and DaaF, controlling the production of S and F1845 fimbriae, respectively, are also functional PapI homologues (17, 39). Therefore, it was rational to assume that AfaF would regulate *clp* expression in the same manner as would the homologous Clp regulator.

A regulatory model for *clp* expression may be proposed (Fig. 3). We have shown previously that both GATC sites are methylated in the absence of Lrp and that methylation protection of these sites requires Lrp but does not require ClpB (28). By analogy to Pap, we postulate that Lrp protects the GATC sites from methylation and cannot bind methylated GATC sites. Lrp presents a lower affinity for  $GATC_{dist}$  than for  $GATC_{prox}$ . The *clp* basal transcription level is low due to the repression exerted by ClpB and Lrp, which is bound to  $GATC<sub>prox</sub>$  (Fig. 3A). Leucine and alanine decrease the affinity of Lrp for  $GATC<sub>prox</sub>$  and repress *clp* basal transcription by a noncharacterized Lrp-independent mechanism (Fig. 3B). AfaF, the PapI homologue, is required for Lrp to bind GATC<sub>dist</sub> and increases the affinity of  $Lrp$  for  $GATC<sub>prox</sub>$ , so that phase variation can occur. The methylation pattern characteristic of phase-ON cells is  $GATC<sub>dist</sub>$  protected from methylation and  $GATC<sub>prox</sub>$ methylated (Fig. 3C), whereas the methylation pattern characteristic of phase-OFF cells is the opposite  $(GATC<sub>dist</sub>$  methylated and GATC<sub>prox</sub> protected) (Fig. 3D). Leucine lowers and alanine prevents Lrp binding to  $GATC<sub>dist</sub>$ . Leucine and alanine thus appear as antagonists of AfaF for Lrp binding to  $GATC<sub>dist</sub>$ . By contrast, alanine acts in conjunction with AfaF to increase Lrp binding to GATC<sub>prox</sub>, so that cells are locked in a highly repressed OFF phase independently of ClpB. Whether maximal repression by alanine also involves the Lrpindependent mechanism cannot be determined (Fig. 3E).

According to this model, a high level of transcription should be expected in the simultaneous absence of Lrp, ClpB, and AfaF (DL844. $\lambda$ 15/1), but this was not the case (276 MU). It has been shown that *pap* transcription is highly repressed by H-NS in the absence of Lrp (38). We could hypothesize that *clp* transcription is moderately repressed by H-NS or another unidentified regulatory protein in the absence of Lrp and ClpB. This repression could be alleviated by Lrp or ClpB individually but amplified by the simultaneous action of Lrp and ClpB.

Without AfaF, about 50% of the DNA molecules were methylated on both GATC sites whereas in the other 50%,  $GATC<sub>prox</sub>$  was protected from methylation. Thus, under these conditions all  $GATC_{dist}$  sites were methylated. A hypothesis to explain this result is that Lrp by itself has no affinity for  $GATC<sub>dist</sub>$  and that Dam and Lrp bind equally to  $GATC<sub>prox</sub>$ , so that at each replication cycle, Lrp binds to half of the  $GATC<sub>prox</sub>$  sites. This pattern was not observed in the presence of AfaF. AfaF by itself had no direct effect on *clp* transcription. Rather, it modified the affinity of Lrp for the GATC sites. In phase-OFF cells, AfaF increased Lrp binding to GATC<sub>prox</sub>, so that this site was protected from methylation in 100% of the DNA molecules, leading to a highly repressed state. In phase-ON cells, AfaF allows Lrp binding to  $GATC_{dist}$ . Thus, Lrp plays dual roles as both an AfaF-dependent activator (when bound to  $GATC_{dist}$ ) and a repressor (when bound to GATC<sub>prox</sub>) of *clp* transcription, similar to its role with the *pap* operon (38).  $GATC_{dist}$  and  $GATC_{prox}$  could be considered activator and repressor sites, respectively. However, *pap* expression is totally abrogated in the absence of PapI (41) whereas *clp* transcription is active in the absence of AfaF. High levels of PapI increase *pap* transcription (34, 38), whereas high levels of AfaF abrogate *clp* expression. Similarly, transcription of *pef* (Pef pili in *S. enterica* serovar Typhimurium) is repressed by PefI, the PapI/AfaF counterpart (32). To explain these differences, Hernday et al. (21) suggested that the binding of Lrp to *pef* sites around  $GATC_{\text{dist}}$  would occur with the highest affinity, with PefI facilitating the transition to the OFF state by movement of Lrp to sites around  $GATC<sub>prox</sub>$ . Clearly, this is not the case for *clp*, as demonstrated by our results. The differences between *clp* and *pap* expression could, instead, be due to different Lrp-binding sites, to divergent nucleotide sequences surrounding the GATC sites, and to the different action of the other regulatory proteins on the promoter region. Indeed, ClpB is a repressor of *clp* expression whereas PapB at physiological levels has no direct influence on the *papBA* promoter.



FIG. 3. Model for control of *clp* expression by Lrp, AfaF, ClpB, and alanine. D and P in open squares represent GATC<sub>dist</sub> and GATC<sub>prox</sub> sites, respectively. B in a triangle represents ClpB. The minus sign in an oval indicates a repressive effect on *clp* basal transcription. (A) Low level of basal transcription in the absence of AfaF and alanine; GATC<sub>dist</sub> is methylated, whereas Lrp is bound to GATC<sub>prox</sub>; ClpB is bound near to the<br>promoter region. (B) Alanine represses the basal transcription independently o  $GATC<sub>prox</sub>$ . (C and D) AfaF bound to Lrp allows Lrp binding to  $GATC<sub>dist</sub>$  in phase-ON cells (C) and increases Lrp binding to  $GATC<sub>prox</sub>$  in phase-OFF cells (D). (E) Alanine prevents the Lrp-AfaF complex from binding to  $GATC<sub>dist</sub>$  and increases its binding to  $GATC<sub>prox</sub>$  locking cells in the OFF phase.

Transcription of *pap* but not of *clp* requires Lrp binding to  $GATC<sub>dist</sub>$  (6, 38) and is highly repressed by H-NS in the absence of Lrp (38). In contrast, the *clp* promoter is moderately active in the absence of Lrp, ClpB, and AfaF, suggesting that H-NS or another unidentified regulatory protein acts as a repressor of *clp* expression less efficiently than does Lrp or ClpB.

Among fimbriae belonging to the P-regulatory family, only CS31A and  $F165<sub>1</sub>$  respond to leucine and alanine levels (10, 19, 28). The synthesis of K99 and type 1 fimbriae is also sensitive to leucine and alanine (11, 14). However, expression of these fimbriae is controlled by a mechanism involving Lrp but is distinct from that of members of the P-regulatory family, and the mode of action of leucine and alanine is not well understood. Two mechanisms by which leucine and alanine repress *clp* transcription were evidenced in this study. First, alanine and leucine repressed the basal transcription about twofold in the absence of Lrp, and this repression required ClpB (Table 1). Second, alanine and leucine altered the methylation patterns in the presence of Lrp, suggesting that they modified the affinity of Lrp for its target sites: in the absence of AfaF, alanine and leucine increased methylation of  $GATC<sub>prox</sub>$  (Table 2). This leads to an increase in the amount of fully methylated DNA. However, fully methylated DNA is probably not associated with the repression of *clp* expression, since *clp* transcription is active in an Lrp-negative background (Table 1). This indicates that the twofold repression observed in the absence of AfaF is due mainly to the Lrp-independent mechanism. In the presence of AfaF, alanine prevented and leucine decreased the AfaF-dependent methylation protection of  $GATC<sub>dist</sub>$ , acting as antagonists of AfaF. In addition, alanine acted in conjunction with AfaF to increase methylation protection of GATC<sub>prox</sub>. These results suggest that alanine and leucine decreased Lrp binding to the site with the lowest affinity  $(GATC<sub>dist</sub>)$  and increased or had no effect, respectively, on Lrp binding to the site with the highest affinity ( $GATC<sub>prox</sub>$ ).

It has been shown that leucine antagonizes the activating action of Lrp on *ilvIH* and *gltBDF* promoters and its repressive effect on the *lysU* promoter by reducing the affinity of Lrp for its binding sites (13,25,37). Zhi et al. (43) have identified Lrpbinding sites in the *dadAX* promoter region. Lrp sites that overlap the *dad* promoters are involved in repression, whereas sites upstream of the promoters are required for activation. Leucine and alanine, which activate *dad* expression, decrease the affinity of Lrp to repressor sites while having little or no effect on the binding of Lrp to activator sites. The inverse situation is found in *clp* expression: leucine or alanine, which represse *clp* expression, increase the methylation protection of the repressor site  $(GATC<sub>prox</sub>)$  and dramatically reduce the

methylation protection of the activator site  $(GATC<sub>dist</sub>)$ . Since methylation protection is very probably due to Lrp binding, in both cases leucine or alanine decreases the binding of Lrp to low-affinity sites. However, in the case of *clp*, an extra protein (AfaF) is required to increase the affinity of Lrp for the repressor site, and leucine and alanine appear as agonists of AfaF. Direct interaction between leucine and Lrp has been demonstrated (27), and Lrp mutations which cause Lrp to be insensitive to leucine have been identified (35). It has been shown that Lrp self-associates in vitro to form a hexadecamer and an octamer and that leucine induces the dissociation of the Lrp hexadecamer to an octamer (8). The authors proposed a model for operons for which the effects of Lrp are potentiated by leucine: the Lrp octamer would bind with moderate affinity, and leucine would potentiate the effect of Lrp by increasing the amounts of leucine-bound octamers. However, the Lrp-mediated regulation of *clp* expression is even more complex, since Lrp binding requires an extra protein such as AfaF.

#### **REFERENCES**

- 1. **Bertin, Y., J. P. Girardeau, A. Darfeuille-Michaud, and C. Martin.** 2000. Epidemiological study of *pap* genes among diarrheagenic *Escherichia coli* strains producing CS31A and F17 adhesins, and characterization of the Pap31A fimbriae. J. Clin. Microbiol. **38:**1502–1509.
- 1a.**Blomfield, I. C.** 2001. The regulation of pap and type 1 fimbriation in *Escherichia coli.* Adv. Microb. Physiol. **45:**1–49.
- 2. **Blyn, L. B., B. A. Braaten, and D. A. Low.** 1990. Regulation of *pap* pilin phase variation by a mechanism involving differential dam methylation states. EMBO J. **9:**4045–4054.
- 3. **Blyn, L. B., B. A. Braaten, C. A. White-Ziegler, D. H. Rolfson, and D. A. Low.** 1989. Phase-variation of pyelonephritis-associated pili in *Escherichia coli:* evidence for transcriptional regulation. EMBO J. **8:**613–620.
- 4. **Braaten, B. A., L. B. Blyn, B. S. Skinner, and D. A. Low.** 1991. Evidence for a methylation-blocking factor (mbf) locus involved in pap pilus expression and phase variation in *Escherichia coli.* J. Bacteriol. **173:**1789–1800.
- 5. **Braaten, B. A., X. Nou, L. S. Kaltenbach, and D. A. Low.** 1994. Methylation patterns in *pap* regulatory DNA control pyelonephritis-associated pili phase variation in *E. coli.* Cell **76:**577–588.
- 6. **Braaten, B. A., J. V. Platko, M. W. van der Woude, B. H. Simons, F. K. de Graaf, J. M. Calvo, and D. A. Low.** 1992. Leucine-responsive regulatory protein controls the expression of both the *pap* and *fan* pili operons in *Escherichia coli.* Proc. Natl. Acad. Sci. USA **89:**4250–4254.
- 7. **Calvo, J. M., and R. G. Matthews.** 1994. The leucine-responsive regulatory protein, a global regulator of metabolism in *Escherichia coli.* Microbiol. Rev. **58:**466–490.
- 8. **Chen, S., M. H. Rosner, and J. M. Calvo.** 2001. Leucine-regulated selfassociation of leucine-responsive regulatory protein (Lrp) from *Escherichia coli.* J. Mol. Biol. **312:**625–635.
- 9. **Contrepois, M., H. C. Dubourguier, A. L. Parodi, J. P. Girardeau, and J. L. Ollier.** 1976. Septicemic *Escherichia coli* and experimental infections of calves. Vet. Microbiol. **12:**109–118.
- 10. **Daigle, F., C. Forget, C. Martin, M. Drolet, M. C. Tessier, H. Dezfulian, and J. Harel.** 2000. Effects of global regulatory proteins and environmental conditions on fimbrial gene expression of F165(1) and F165(2) produced by *Escherichia coli* causing septicaemia in pigs. Res. Microbiol. **151:**563–574.
- 11. **de Graaf, F. K., P. Klaasen-Boor, and J. E. van Hees.** 1980. Biosynthesis of the K99 surface antigen is repressed by alanine. Infect. Immun. **30:**125–128.
- 12. **Di Martino, P., Y. Bertin, J. P. Girardeau, V. Livrelli, B. Joly, and A. Darfeuille-Michaud.** 1995. Molecular characterization and adhesive properties of CF29K, an adhesin of *Klebsiella pneumoniae* strains involved in nosocomial infections. Infect. Immun. **63:**4336–4344.
- 13. **Ernsting, B. R., J. W. Denninger, R. M. Blumenthal, and R. G. Matthews.** 1993. Regulation of the *gltBDF* operon of *Escherichia coli:* how is a leucineinsensitive operon regulated by the leucine-responsive regulatory protein? J. Bacteriol. **175:**7160–7169.
- 14. **Gally, D. L., J. A. Bogan, B. I. Eisenstein, and I. C. Blomfield.** 1993. Environmental regulation of the *fim* switch controlling type 1 fimbrial phase variation in *Escherichia coli* K-12: effects of temperature and media. J. Bacteriol. **175:**6186–6193.
- 15. **Garcia, M. I., P. Gounon, P. Courcoux, A. Labigne, and C. Le Bouguenec.** 1996. The afimbrial adhesive sheath encoded by the *afa-3* gene cluster of pathogenic *Escherichia coli* is composed of two adhesins. Mol. Microbiol. **19:**683–693.
- 16. **Girardeau, J. P., M. Der Vartanian, J. L. Ollier, and M. Contrepois.** 1988. CS31A, a new K88-related fimbrial antigen on bovine enterotoxigenic and septicemic *Escherichia coli* strains. Infect. Immun. **56:**2180–2188.
- 17. **Goransson, M., K. Forsman, and B. E. Uhlin.** 1988. Functional and structural homology among regulatory cistrons of pili-adhesin determinants in *Escherichia coli.* Mol. Gen. Genet. **212:**412–417.
- 18. **Goransson, M., P. Forsman, P. Nilsson, and B. E. Uhlin.** 1989. Upstream activating sequences that are shared by two divergently transcribed operons mediate cAMP-CRP regulation of pilus-adhesin in *Escherichia coli.* Mol. Microbiol. **3:**1557–1565.
- 19. **Harel, J., F. Daigle, C. Forget, M. C. Tessier, C. Crost, and C. Martin.** 2000. Phase variation of F165(1) (Prs-like) fimbriae from *Escherichia coli* causing septicaemia in animals. Can. J. Microbiol. **46:**1101–1107.
- 20. **Henderson, I. R., P. Owen, and J. P. Nataro.** 1999. Molecular switches—the ON and OFF of bacterial phase variation. Mol. Microbiol. **33:**919–932.
- 21. **Hernday, A., M. Krabbe, B. Braaten, and D. Low.** 2002. Self-perpetuating epigenetic pili switches in bacteria. Proc. Natl. Acad. Sci. USA **99**(Suppl. 4)**:**16470–16476.
- 22. **Huisman, T. T., D. Bakker, P. Klaasen, and F. K. de Graaf.** 1994. Leucineresponsive regulatory protein, IS1 insertions, and the negative regulator FaeA control the expression of the *fae* (K88) operon in *Escherichia coli.* Mol. Microbiol. **11:**525–536.
- 23. **Jallat, C., A. Darfeuille-Michaud, J. P. Girardeau, C. Rich, and B. Joly.** 1994. Self-transmissible R plasmids encoding CS31A among human *Escherichia coli* strains isolated from diarrheal stools. Infect. Immun. **62:**2865–2873.
- 24. **Kaltenbach, L. S., B. A. Braaten, and D. A. Low.** 1995. Specific binding of PapI to Lrp-pap DNA complexes. J. Bacteriol. **177:**6449–6455.
- 25. **Lin, R., B. Ernsting, I. N. Hirshfield, R. G. Matthews, F. C. Neidhardt, R. L. Clark, and E. B. Newman.** 1992. The *lrp* gene product regulates expression of *lysU* in *Escherichia coli* K-12. J. Bacteriol. **174:**2779–2784.
- 26. **Low, D. A., B. A. Braaten, and M. van der Woude.** 1996. Fimbriae, p. 146–157. *In* F. C. Neidhardt, R. Curtiss III, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger (ed.), *Escherichia coli* and *Salmonella:* cellular and molecular biology, 2nd ed. ASM Press, Washington, D.C.
- 27. **Marasco, R., M. Varcamonti, F. La Cara, E. Ricca, M. De Felice, and M. Sacco.** 1994. In vivo footprinting analysis of Lrp binding to the *ilvIH* promoter region of *Escherichia coli.* J. Bacteriol. **176:**5197–5201.
- 28. **Martin, C.** 1996. The *clp* (CS31A) operon is negatively controlled by Lrp, ClpB, and L-alanine at the transcriptional level. Mol. Microbiol. **21:**281–292.
- 29. **Martin, C., C. Boeuf, and F. Bousquet.** 1991. *Escherichia coli* CS31A fimbriae: molecular cloning, expression and homology with the K88 determinant. Microb. Pathog. **10:**429–442.
- 30. **Miller, J. H.** 1972. Experiments in molecular genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
- 31. **Newman, E. B., and R. Lin.** 1995. Leucine-responsive regulatory protein: a global regulator of gene expression in *E. coli.* Annu. Rev. Microbiol. **49:**747– 775.
- 32. **Nicholson, B., and D. Low.** 2000. DNA methylation-dependent regulation of *pef* expression in *Salmonella typhimurium.* Mol. Microbiol. **35:**728–742.
- 33. **Nou, X., B. Braaten, L. Kaltenbach, and D. A. Low.** 1995. Differential binding of Lrp to two sets of pap DNA binding sites mediated by Pap I regulates Pap phase variation in *Escherichia coli.* EMBO J. **14:**5785–5797.
- 34. **Nou, X., B. Skinner, B. Braaten, L. Blyn, D. Hirsch, and D. Low.** 1993. Regulation of pyelonephritis-associated pili phase-variation in *Escherichia coli:* binding of the PapI and the Lrp regulatory proteins is controlled by DNA methylation. Mol. Microbiol. **7:**545–553.
- 35. **Platko, J. V., and J. M. Calvo.** 1993. Mutations affecting the ability of *Escherichia coli* Lrp to bind DNA, activate transcription, or respond to leucine. J. Bacteriol. **175:**1110–1117.
- 36. **Powell, B. S., M. P. Rivas, D. L. Court, Y. Nakamura, M. P. Rivas, and C. L. Turnbough.** 1994. Rapid confirmation of single copy lambda prophage integration by PCR. Nucleic Acids Res. **22:**5765–5766.
- 37. **Ricca, E., D. A. Aker, and J. M. Calvo.** 1989. A protein that binds to the regulatory region of the *Escherichia coli ilvIH* operon. J. Bacteriol. **171:**1658–1664.
- 38. **van der Woude, M. W., L. S. Kaltenbach, and D. A. Low.** 1995. Leucineresponsive regulatory protein plays dual roles as both an activator and a repressor of the *Escherichia coli pap* fimbrial operon. Mol. Microbiol. **17:**303–312.
- 39. **van der Woude, M. W., and D. A. Low.** 1994. Leucine-responsive regulatory protein and deoxyadenosine methylase control the phase variation and expression of the *sfa* and *daa* pili operons in *Escherichia coli.* Mol. Microbiol. **11:**605–618.
- 40. **Weyand, N. J., and D. A. Low.** 2000. Regulation of *pap* phase variation—Lrp is sufficient for the establishment of the phase off *pap* DNA methylation pattern and repression of *pap* transcription in vitro. J. Biol. Chem. **275:**3192–3200.
- 41. **White-Ziegler, C. A., M. L. Angus Hill, B. A. Braaten, M. W. van der Woude, and D. A. Low.** 1998. Thermoregulation of *Escherichia coli pap* transcription: H-NS is a temperature-dependent DNA methylation blocking factor. Mol. Microbiol. **28:**1121–1137.
- 42. **Xia, Y., K. Forsman, J. Jass, and B. E. Uhlin.** 1998. Oligomeric interaction of the PapB transcriptional regulator with the upstream activating region of pili adhesin gene promoters in *Escherichia coli.* Mol. Microbiol. **30:**513–523.
- 43. **Zhi, J., E. Mathew, and M. Freundlich.** 1999. Lrp binds to two regions in the *dadAX* promoter region of *Escherichia coli* to repress and activate transcription directly. Mol. Microbiol. **32:**29–40.